Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Status unconfirmed · Phase 2

Conditions studied: Non Small Cell Lung Cancer

In brief

This is a pilot study using \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The main objectives of the study are to quantify the change in \[18F\]F AraG PET signal before and after CkIT therapy, and to correlate this change in \[18F\]F AraG PET signal with a radiographic response.

Key facts

Study ID

NCT04726215

Run by

CellSight Technologies, Inc.

People needed

50

Starts

2021-04-15

Expected to finish

2024-10-15

Last updated by the study team

2023-09-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a histologically confirmed NSCLC and planned to undergo immunotherapy as monotherapy or as combination therapy with concurrent as treatment for advanced/metastatic disease.
• RECIST measurable disease.
• ECOG performance status of 0, 1 or 2.
• Life expectancy >/= 6 months at enrollment.

You may not qualify if…

• Serious comorbidities that in the opinion of the investigator/sponsor could compromise protocol objectives.
• Pregnant women or nursing mothers.
• Patients with severe claustrophobia.

Where it is running

• Palo Alto Veterans Institute of Research — Palo Alto, California, United States (enrolling)
• Sutter Cancer Center — Sacramento, California, United States (enrolling)
• Stony Brook University — Stony Brook, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.